Novo Nordisk Faces Setbacks: Obesity Drug Trial Results and Hims & Hers Deal Termination

Novo Nordisk's Obesity Drug Pipeline Concerns

• 💡 Kagrima, a next-generation obesity drug from Novo Nordisk, showed similar weight loss to Eli Lilly's Zeppbound but with slightly more side effects.
• ⚠️ Another Novo Nordisk drug, Amirretin, demonstrated promising weight loss in early trials but raised concerns due to concerning rates of side effects.
• 📉 These results have led to doubts about Novo Nordisk's drug pipeline and negatively impacted its stock.

Termination of Hims & Hers Collaboration

• 🚫 Novo Nordisk is pulling its drug MGOI from telehealth platforms Hims & Hers just one month after launching the collaboration.
• 🎯 The decision stems from Hims & Hers continuing to sell compounded GLP1s, which Novo Nordisk claims violates laws prohibiting mass sales of compounded drugs under the guise of personalization.
• ⚖️ Novo Nordisk's statement cited false marketing that puts patient safety at risk, raising questions about potential legal fallout.
• ❓ It remains unclear why Novo Nordisk made this decision now, as Hims & Hers had not indicated they would stop selling compounded drugs.

Eli Lilly's Positive Developments

• ✅ In contrast, Eli Lilly had a successful weekend at the ADA conference in Chicago.
• 📊 Lilly presented full results for its obesity pill, showing no significant increase in side effects or liver toxicity, contrary to some fears.
• 🚀 Investors are expressing relief, with some suggesting Eli Lilly has won the race in the obesity drug market.
• 🗓️ The Lilly obesity pill is anticipated to be available as soon as next year, with more obesity-specific results expected in the third quarter.